Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

;All manufacturing costs for KRYSTEXXA after FDA approval are recorded as inventory as opposed to research and development prior to approval.

Selling, general and administrative expenses increased $15.0 million to $22.3 million for the three months ended September 30, 2011, from $7.3 million for the three months ended September 30, 2010.  The higher expenses for the three months ended September 30, 2011 were primarily due to increased selling and marketing expenses associated with the full commercial launch of KRYSTEXXA.  

Interest expense on the Company's convertible notes was $3.4 million for the three months ended September 30, 2011.

Conference Call and WebcastThe Company will host a live conference call and webcast beginning at 9:00 a.m. Eastern Time on November 3, 2011 to discuss these results and to answer questions.  To participate by telephone, please dial:Domestic:

866-393-9370 International:

706-679-1207 Conference ID:

17722127The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary. A telephone replay will be available from 12:00 p.m. Eastern Time on November 3, 2011 through 12:00 a.m. Eastern Time on November 17, 2011 by dialing:Domestic:

855-859-2056 or 800-585-8367 International:

404-537-3406 Conference ID:

17722127ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Moun
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
2. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
3. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
4. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
5. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
6. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
7. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
8. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
9. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
10. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
11. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Fla. , Aug. 1, 2014 Dyadic ... whose patented and proprietary technologies are used to develop, ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... the second quarter ended June 30, 2014 after market ... a conference call that day at 5:00 p.m. Eastern ...
(Date:7/31/2014)... , July 31, 2014  According to data released ... the 2015 average monthly Medicare Part D premium is ... lower than was originally projected, the Pharmaceutical Care Management ... program continues to be a bright spot in American ... in each region and using cutting edge, cost-saving tools ...
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... ALLEGAN, Mich., May 10, 2011 Perrigo Company (Nasdaq: ... to settle all Hatch-Waxman litigation relating to fluticasone lotion brought ... relevant patents. Under the terms of the settlement, Perrigo can ... 22, 2012, or earlier under certain circumstances. ...
... Tenn., May 10, 2011 MedQuist Holdings Inc. (NASDAQ: ... transcription services and technology-enabled clinical documentation workflow solutions, today ... St. Joseph,s Hospital Health Center in Syracuse, New York, ... projected to achieve significant cost savings and improve efficiency ...
Cached Medicine Technology:Perrigo Announces Settlement of Cutivate Lotion Litigation 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 3
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... NV (PRWEB) August 01, 2014 ... opportunities for independent community pharmacies. At ThoughtSpot 2014, ... are equipped with practices and resources to enhance ... AmerisourceBergen leaders focused on critical issues to give ... optimize and grow. , ThoughtSpot show attendance ...
(Date:8/1/2014)... Dallas, Texas (PRWEB) August 01, 2014 ... universal health coverage and healthcare reforms are boosting ... price of medicines through discounts and increasing generic ... stood at approximately 76.7 million in 2013, having ... of 1.4%, from 2008. The implementation of the ...
(Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... importance of a nutritious lunch towards maintaining a healthy ... Commonwealth Games gold medal marathon runner// and mother of ... Dr John Tickell, and award-winning chef Michael Moore. ... to encourage Australians to make a healthy lunch a ...
... which are mainly used to prevent blocking of various arteries ... patients require other procedures// such as angioplasty or a by ... flexible nickel-titanium tubes. They are very effective in ... Researchers conducted a new study and published it in the ...
... that they are requesting patients to take a blood ... for a blood test for HIV and Hepatitis. Scripps ... nurse had failed to follow proper sterilization procedures for ... the so-called stomach-stapling operations. The instrument requires a different ...
... look into the costs of healthcare, met in Adelaide, and ... extremely high and has no system of prioritising patients. ... reason for wanting her breasts reduced has to wait just ... aesthetic reasons. Women who were in need for the surgery ...
... meet this week in Abuja, Nigeria, to review the progress ... malaria, tuberculosis. ,Five years ago the leaders had ... 15 per cent of national budgets in order to accelerate ... as other diseases. ,However progress has been dismal. ...
... carry a potential risk of suffering asthma, than compared to ... is published in the May 1 issue of Environmental Health ... 75 meters (about 82 yards) of a major road had ... in the past year than were children who lived more ...
Cached Medicine News:Health News:Celebrities Promote Healthy Lunch 2Health News:Waiting Period Of Over 10yrs For Women Needing Breast Reduction Surgery 2Health News:Review of Reversal of Spread of Diseases in Africa 2Health News:Asthma Risk Pronounced In Children Living Close to Traffic Ridden Roads 2
... EasyID is a patient identification ... cost savings by eliminating embossers, imprinters ... efficiency and workflow throughout the facility. ... patient identification and is designed to ...
The Metrologic MS9520 Voyager is a high performance single line laser bar code scanner with automatic activation and sophisticated data transmission via Metrologic proprietary CodeGate technology....
... latex-free, thermal transfer wristband for printing ... images that resist smears and abrasion ... cleaners, and blood. A time-tested and ... patron management applications. A tamper-evident VOID ...
... Durable, secure, direct thermal wristband ... entertainment venue patron admissions. Its clip ... five colors plus white for color ... Zebra printers for peak performance. Print ...
Medicine Products: